Kim Jinuk, Kim Jeesoo, Choi Chulwon, Bae Jungnam, Choi Hee-Jung
Department of Biological Sciences, Seoul National University, Seoul, Republic of Korea.
Division of Biological Science and Technology, Yonsei University, Wonju, Republic of Korea.
Exp Mol Med. 2025 Jul 8. doi: 10.1038/s12276-025-01497-y.
Recent advances in structural biology have profoundly enhanced our understanding of G protein-coupled receptors (GPCRs), providing detailed molecular insights into their activation and ligand recognition. Here, in this Review, we explore the molecular mechanisms of class A and class B GPCRs bound to peptide agonists and their implications for drug development. We examine representative GPCRs, such as the angiotensin II type 1 receptor, chemokine receptor 5, μ-opioid receptor, parathyroid hormone 1 receptor and glucagon-like peptide 1 receptor (GLP-1R), highlighting their activation processes upon peptide ligand binding. Comparative analysis of structures bound to endogenous and synthetic peptide ligands reveals critical insights for rational drug design. A case study on GLP-1R demonstrates how structural insights have led to the design of successful drugs for type 2 diabetes and obesity. This comparative structural analysis aims to deepen our understanding of GPCR activation mechanisms and support future drug discovery efforts targeting peptide-binding GPCRs.
结构生物学的最新进展极大地增进了我们对G蛋白偶联受体(GPCRs)的理解,为其激活和配体识别提供了详细的分子见解。在本综述中,我们探讨了与肽类激动剂结合的A类和B类GPCRs的分子机制及其对药物开发的影响。我们研究了代表性的GPCRs,如血管紧张素II 1型受体、趋化因子受体5、μ-阿片受体、甲状旁腺激素1受体和胰高血糖素样肽1受体(GLP-1R),重点介绍了它们在肽配体结合后的激活过程。对与内源性和合成肽配体结合的结构进行比较分析,为合理药物设计提供了关键见解。以GLP-1R为例,展示了结构见解如何促成了用于治疗2型糖尿病和肥胖症的成功药物的设计。这种比较结构分析旨在加深我们对GPCR激活机制的理解,并支持未来针对结合肽的GPCRs的药物发现工作。